Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Corporate Presentation

Updated as of October, 2018

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the total amount of SEK 80,000,000 with...
Read more

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 29 November 2017, on 18 April 2018 and on 7 September 2018, issued convertible loans with total nominal amount of MSEK...
Read more

Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma

Overall response rate data from the (RXE) Phase II study conducted in the US and Sweden met its primary end points and treatment with Doxophos Vet was generally well tolerated. Oasmia’s assessmen...
Read more
To news archive